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Background: Pancreatic cancer (PAC) patients experience a high rate of locoregional recurrences and distant
metastasis finally leading to their demise even after curatively-intended multidisciplinary treatment approaches
including surgery, chemotherapy and radiotherapy. However, clinical reports on bone and brain metastases in PAC
patients are extremely rare and thus timing and dose description are not well defined. Our work therefore
summarizes a mono-institutional experience on the use of radiotherapy (RT) for PAC patients with metastatic
disease with the aim of identifying overall survival and treatment response in this rarely reported patient group.
Method: Forty-four PAC patients with 66 metastatic lesions were treated with palliative radiotherapy (RT). Thirty-three
patients (48 lesions), 7 patients (11 lesions) and 5 patients (7 lesions) with bone, liver and brain metastases analyzed
respectively were analyzed; one patient had both bone and cerebral metastases and was treated for the lesions,
thus including him in both subgroups. Indications for RT were pain, neurological impairment, risk of pathological
fracture or imminent danger for development of any of these conditions in case of tumor progression. Median age
was 64 years (range 38 to 78 years) and there were 27 male (61%) and 17 (39%) female patients. Analyses of overall
survival (OS) and local control were performed. OS was calculated from the first day of RT.
Results: Median overall survival (mOS) of all patients after start of RT was 4.2 months. Survival rates after 1, 3 and 6
months were 79.3%, 55.3% and 30.3% respectively. Patients presenting with bone metastasis had a mOS of 3.1
months and after 1, 3 and 6 months, survival rates were 75.3%, 46.5% and 19.9% respectively. Symptomatic
response to therapy was recorded in 85% of all evaluated patients with bone metastasis. Patients undergoing
radiosurgery because of liver metastasis were locally controlled in all but one patient after a median follow-up of
8.3 months.
Conclusion: Overall survival of all patients with metastatic disease was considerably worse. A major goal for the
future must be the selection of an appropriate RT treatment in terms of duration and technique for these PAC
patients.
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Pancreatic cancer (PAC) patients experience a high rate
of locoregional recurrences and distant metastasis finally
leading to their death even after curatively-intended
multidisciplinary treatment approaches including sur-
gery, chemotherapy and radiotherapy [1,2]. To date,
concepts with pure palliative aim can be separated from
semi-curative treatment for oligometastasized lesions
due to the biological differences of the underlying dis-
ease. Local intensified treatment options of isolated
local recurrences consist of either radical surgical ap-
proaches or neoadjuvant chemoradiation in case of
unresectability [3-5]. In cases of peritoneal metastasis
which frequently occur or in cases of distant metastasis
predominantly to the liver and lungs, systemic therapy
with, for example, FOLFIRINOX or gemcitabine (GEM)
or other novel approaches including molecular targeted
treatments, is the palliative treatment of choice with im-
pact on overall survival (OS) compared to observation
alone [6]. The landmark trial of the PRODIGE-group
that introduced FOLFIRINOX as the new standard of
care for PAC patients with metastatic disease showed a
median overall survival (mOS) of approximately 11
months compared to 6.8 months for the GEM group;
however only patients with a good performance status
(ECOG 0 or 1) were included. This explains the worse
outcome with a mOS of only 5.7 months in the GEM-
group of the initial trial of [7] that favored GEM over
fluorouracil [7]. As clinical trial patient groups are highly
selected, one may consider a shorter OS for many patients
after diagnosis [8,9].
Whereas liver, lung and peritoneal metastases are often
diagnosed in PAC patients during the treatment or follow-
up period, knowledge on the incidence of bone, soft tissue
and brain metastases is limited. While brain metastases
can lead to life threatening conditions by inducing perifo-
cal edema and to a sudden decline in vigilance or head-
aches, seizures, nausea and dizziness, bone metastases
may cause pain and can lead to pathological fractures and
spinal cord compression with consecutive serious neuro-
logical symptoms [10,11]. However, palliative radiotherapy
has shown high efficacy in palliation and prevention of
symptoms in gastrointestinal cancer [12,13].
Today, clinical reports on bone and brain metastases
in PAC patients are relatively rare and thus timing and
dose description regimens in this tumor entity are not
well defined [14-16]. Especially in the palliative setting,
intensity and appropriateness of any therapy has to be
well chosen and adapted to the patients’ individual prog-
nosis to avoid overtreatment by applying longer treat-
ment schedules than are necessary [17,18].
To provide a data basis for subsequent clinical study
concepts in the oligometastasized situation as well as
patients with a disseminated disease status, our worksummarizes a mono-institutional experience on the use of
radiotherapy (RT) for PAC patients with metastatic dis-
ease with the aim of determining survival after RT and
treatment response in this rarely reported patient group.
Methods
Patient characteristics
From 1997 to 2011, a total of 44 PAC patients with meta-
static disease incorporating 66 lesions were treated with
palliative radiation therapy (RT). Hereof, 33 patients (48
lesions) presented with bone metastases, 7 patients (11
lesions) with liver metastases, and 5 patients (7 lesions)
with brain metastases. Indications for RT depended on the
location of the lesions and included pain, neurological
impairment, risk of pathological fracture or imminent
danger for development of any of these conditions in
case of tumor progression as a means of ‘prospective palli-
ation’. All patients were discussed in an interdisciplinary
setting. Median age was 64 years (range 38 to 78 years)
and there were 27 male (61%) and 17 (39%) female pa-
tients. All patient characteristics are shown in Table 1. Our
study was approved by the Institutional Review Board/the
independent Ethics Committee of the Medical Faculty
Heidelberg (reference number: S-483/2011).
Radiotherapy
Treatment of bone, brain and liver metastases was per-
formed using LINAC-based external-beam radiotherapy.
For brain metastases, fixation with an individual mask fix-
ation was performed as described previously [2,19]. For
whole brain radiotherapy (WBRT), two opposed lateral
fields were applied. Stereotactic radiosurgery (SRS) was per-
formed after individual mask fixation using Scotchcast ma-
terial, and computed tomography (CT) imaging was
performed with the stereotactic base frame attached to
the mask [19,20]. CT imaging with and without contrast
enhancement, as well as contrast-enhanced magnetic res-
onance imaging (MRI) were used for target volume de-
lineation. We defined the gross tumor volume (GTV) as
the contrast-enhancing lesion on CT and MRI, and added a
planning target volume (PTV) of 1 to 2 mm. Dose prescrip-
tion was performed according to the size and the location
of the lesion following the guidelines by Shaw et al. [21].
Confirmation of bone metastasis was performed radio-
logically by CTand in some cases also by bone scintigraphy.
As described above, the standard radiotherapy proto-
cols include fractionation regimen of 10 × 3 Gy (20 le-
sions, 30%) and 20 x 2 Gy (18 lesions, 27%) (Table 2). In
49% of all treatments (33/67 lesions), a hypofractiona-
tion protocol was applied with single fractions between
2.5 and 4 Gy. In 42% of the irradiated metastases (28/67
lesions), a normofractionated schedule with single frac-
tions of 1.8 Gy or 2 Gy were applied. In a further six
cases, patients firstly underwent a normofractionation
Table 1 Patients with bone metastasis - details and
treatment characteristics






Neurological impairment 4/48 (8%)
Radiotherapy
Overall dose (median, range) 30 Gy (3 to 40 Gy)
Single dose (median, range) 3 Gy (2 to 8 Gy)
Number of fractions (median, range) 10 (1 to 20)
Number of applied doses≥ 30 Gy 38
Number of treatment schedules≥ 20 days 10
Most frequent treatment schedules 10 x 3 Gy, 26 lesions (54%)
Short Protocol (SF 4 or 8 Gy) 5/48 lesions (10%)
Conventional fractionation (SF 2/2.5 Gy) 11/48 lesions (23%)
Treatment duration (median, range) 15 (1 to 30 days)
Early discontinuation 7/48 lesions (15%)
Previous systemic treatment 26 (79%)
Symptom response 18/33 (55%)
Localization
Spine 30 (63%)
Upper/lower extremities 2 (4%)
Pelvis 8 (17%)





Table 2 Patients with liver metastasis - details and
treatment characteristics
Patient and treatment details Number
Patient number 7
Number of lesions 11
Age (median, range) (years) 64 (53 to 78)
Irradiation of two lesions in one
session (patient number)
4





Tomotherapy (number of patients/lesions) ½
Dose at 80%-isodose (median, range) (Gy) 24 (20 to 28)






Previous systemic treatment 5 (71%)
RS, radiosurgery.
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of a worsening of the performance status.
Radiotherapy was usually performed five days per week.
The median treatment time was 15 days. In case of radio-
therapy to bone metastases in the spine, the target volume
included the non-invaded adjacent vertebral bodies (cranial
and caudal direction).
A total of 35 patients were previously treated with sys-
temic agents (predominantly gemcitabine-containing regi-
mens) and none of them received concomitant systemic
treatment during palliative RT according to our institu-
tional guidelines.
Liver metastases were irradiated using our in-house
standard protocol as described previously [4,5,22]. In
brief, patients were immobilized using an individually
shaped vacuum pillow and an abdominal compression to
reduce the liver movement. A contrast agent enhancedCT scan and a 4D-CT series for quantifying liver motion
was acquired for treatment planning. The extracranial
stereotactic set-up has been developed at the German
cancer research center (dkfz) and is commercially avail-
able (Leibinger, Freiburg, Germany). The patient is posi-
tioned in an individually shaped vacuum pillow (Brandis
Medizintechnik, Weinheim, Germany). The intra-corporal
movement of the liver was reduced by epigastric compres-
sion using a triangular Plexiglas or carbon plate. Fixation
of the plate is performed by two bars, which are firmly at-
tached to the metal or carbon arch. A Siemens Somatom
Plus 4 (Siemens, Erlangen, Germany) was used for treat-
ment planning. A spiral CT scan with 5-mm slice thick-
ness and 500-mm field of view was performed which
included the localization system. The patients were ad-
vised to breathe normally during the scanning time
without taking deep breaths.
On the treatment day, patients were repositioned in the
above mentioned setting using pen marks and another
control CT scan. Until the year 2003, CT imaging was per-
formed offline, and, if positioning was adequate; patients
were brought to the linear accelerator (LINAC) using an
individual shuttle system leaving the patient in the vac-
uum bag/abdominal press fixation. In recent years (2004
to 2009), LINACs (for example, Siemens Artiste, Siemens
Healthcare, Erlangen, Germany) were equipped with
on-board imaging as, for example, in case of tomother-
apy, a combination of the 6 MeV LINAC with CT im-
aging. Target and OAR contouring was performed using
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Sector Healthcare, Erlangen, Germany), and inverse
treatment planning was conducted applying the Hi-ART
Tomotherapy planning software (TomoTherapy Inc.,
Madison, WI, USA). Dose constraints for adjacent or-
gans at risk and the liver were used according to Emami
et al. and Dawson et al. [23,24]. In the current analysis
we included data on patients which were already de-
scribed in a previous report on radiosurgery (RS) for
liver metastasis from our institution [4,5].
Follow-up and statistics
Overall survival was calculated from the first day of irradi-
ation until death. Information on follow-up with radio-
logical data on treatment response was available in 29 of
44 patients (66%). The log-rank test was implemented to
compare survival curves evaluating the association be-
tween clinical variables of interest and survival. All cal-
culations were performed using the statistical software
program SPSS 18.0 for Windows (Chicago, IL, US).
Results
Median survival of all patients was 4.2 months (95%
confidence interval (CI) 2.4 to 6.0). Survival rate after 1,
3 and 6 months was 79.3%, 55.3% and 30.3% respect-
ively (Figure 1).Figure 1 Kaplan-Meier survival curve of all patients.Patients with bone metastasis
There was a total number of 33 patients with 48 bone le-
sions. Lesion and treatment details are listed in Table 1.
Patients presenting with bone metastasis had a mOS of
3.1 months (95% CI 1.9 to 4.3) and after 1, 3 and 6
months, survival rates were 75.3%, 46.5% and 19.9% re-
spectively. RT indications were as follows: pain in 44 of
48 lesions (92%), spinal instability in 24 of 48 cases
(50%) and consecutive neurological impairment in 4
cases (8%). Localization of the bone lesions was predom-
inantly the spine in 30 cases (63%), the pelvis in 8 cases
(17%) and the upper and lower extremities in 2 (4%), the
shoulder in 4 (8%), ribs in 2 (4%) and the skull base in 3
(6%) cases. Treatment protocols varied but most patients
were treated with 30 Gy in 10 fractions (26 lesions,
54%). Treatment protocols with single doses of 4 and 8
Gy were documented in 5 lesions (10%), while conven-
tional fractionation with single doses of 2 or 2.5 Gy were
applied in 11 cases (23%). The median number of ap-
plied fractions was 10 (range 1 to 20). In 38 cases (86%)
the prescribed overall dose was greater than or equal to
30 Gy. Median treatment duration was 15 days (range 1
to 30 days). An early discontinuation was recorded for 8
treatments (17%). Symptomatic response to RT was con-
firmed in at least 26 of 30 cases (87%). There was no
clinical follow-up for the remaining patients.
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A total of five patients with seven brain metastases were
analyzed. The median age was 59 years (range 41 to 77)
and two patients had multiple lesions (defined as more
than 3 lesions synchronously) (Table 3). Three patients
had one to three metastases at the time of RT. In all pa-
tients there were additional confirmed extra-CNS metas-
tases. Mean survival of patients was 6.3 months (95% CI
3.9 to 8.6). A total of two patients with four cerebral le-
sions underwent LINAC-based stereotactic radiosurgery
with doses of 18 Gy and 20 Gy prescribed to the sur-
rounding 80%-isodose line. Localization of these four le-
sions was the cerebellum, the right and left parietal lobe
and the left frontal lobe. WBRT, because of multiple in-
tracerebral lesions was performed in three patients with
a total dose of 30 Gy in 10 fractions (two patients) or 40
Gy in 20 fractions applied with two lateral opposed beams.
Three out of four evaluated patients responded to RT in
terms of improved neurologic function or reduced lesion
size. One patient had a progressive intracerebral lesion at
time of the first follow-up MRI.
Patients with liver metastasis
Seven patients with eleven lesions were treated with
high-dose stereotactic radiosurgery (six patients with
nine lesions) or helical intensity-modulated radiosurgery
(tomotherapy, one patient with two lesions) (Table 2).
The median prescribed dose to the 80%-isodose line was
24 Gy (range 20 to 28 Gy). In four patients, irradiation
of two lesions in one treatment session was performed.
Only one local failure was diagnosed during follow-up
and occurred 1.4 months after treatment. All other le-
sions were locally controlled during a mean follow-up
period of 5.4 months (range 1.4 to 20.2 months). All pa-
tients have deceased during follow-up and mOS was 8.3
months (range 4.2 to 31.9 months). Of these patients,Table 3 Patients with brain metastasis - details and
treatment characteristics
Patient and treatment details Number
Patient number 5
Number of lesions 7
Age (median, range) (years) 59 (41 to 77)
Multiple lesions (≥3 lesions; patient number) 2
One to three lesions (patient number) 3
Extra-CNS metastases (patient number) 5
Radiotherapy
Stereotactic radiosurgery (number of patients/lesions) 2/4
Dose at 80%-isodose (median, range) (Gy) 20 (18 to 20)
WBRT (number of patients) 3
Previous systemic treatment 4 (80%)
WBRT, whole brain radiotherapy.71.4% survived the first 6 months after RT and after 12
months, 2 patients were still alive (18%).
Discussion
This is the first report describing a rare group of patients
with metastasized PAC in bone, liver and brain undergo-
ing palliative RT treatment. According to our analysis,
mOS of the entire group is comparably short at 4.2
months after initiation of RT. Palliation or prevention of
clinically relevant symptoms was achieved in a high
number of patients although follow-up with medical im-
aging and clinical examination was very short; due to
the palliative nature of the treatment, in some patients
follow-up did not included imaging or was only per-
formed depending on the performance status of the pa-
tient. In our subset of patients with bone metastasis,
symptomatic response was recorded in 85% after RT and
proved therefore a trend in efficacy. Local failure after
RS treatment of liver metastasis in oligometastasized pa-
tients was only recorded in one lesion out of eleven le-
sions in seven patients. RS is a safe and a non-invasive
treatment method in this patient group and can be applied
in one session without the disadvantages of prolonged
treatment duration over several weeks.
A relatively short follow-up period may be explained
by the generally dismal prognosis of this patient group
with reported median survival times of only several
months or even weeks [6,7]. Even though efficacy of RT
in palliating symptoms derived from brain or bone me-
tastasis is well known, treatment duration plays an im-
portant role especially in poor-prognosis patients. The
radiation oncologist has to decide carefully about the ap-
propriate treatment schedule in terms of dose prescrip-
tion and duration. Customizing radiation treatment in
cancer patients with advanced and metastatic disease
with respect to their remaining lifetime is difficult and in
most cases depends on the physicians’ personal opinion.
Gripp et al. examined how palliative patients’ survival
related to physicians’ subjective prediction and objective
prognostic factors and concluded that prediction was
poor, especially in patients with a remaining life expect-
ancy of less than one month [17]. In general, clinician-
predicted survival (CPS) is controversial and many reports
point to imprecise and overly optimistic predictions in ter-
minally ill cancer patients [25-29].
Recently Holmebakk et al. described CPS by surgeons
for palliative patients and found a prognostic accuracy of
only 28% for the subgroup of PAC patients [30]. Clinical
researchers from the MSKCC therefore invented a nor-
mogram for the prediction of an individual PAC patient
that was recently validated from de Castro et al. [31].
In a subgroup of hepatocellular and cholangiocellular
carcinoma patients with bone metastasis, our group re-
cently found a comparable poor mOS with 3.4 months
Habermehl et al. European Journal of Medical Research 2014, 19:24 Page 6 of 7
http://www.eurjmedres.com/content/19/1/24compared to 3.1 months of the corresponding subgroup
in our current analysis [12]. Analysis of prescribed RT
protocols demonstrated a clear trend towards longer
treatment schedules and thus longer hospitalization
rates in terminally ill cancer patients. In a large number
of cases, RT protocol included 20 fractions of 2 Gy and
single fraction treatments were not recorded. A total of
30% of all treatments (20/66 lesions), patients were
treated for more than 20% of their remaining lifetime,
and in five patients treatment lasted longer than 50% of
the remaining lifetime.
The dismal prognosis of our patient cohort is certainly
based on the considerably high metastatic potential of
the underlying PAC. All analyzed patients with brain
metastases and two out of seven patients treated for liver
metastases had further metastasis outside of these or-
gans. A total of four patients of the liver metastasis
group had multiple lesions. Therefore, PAC patients with
metastatic disease are rather unlikely to present at an
oligometastasized stage with one to four metastases. The
poor prognosis of PAC patients is a result of a highly ag-
gressive local and distant dissemination pattern of the
disease. A group of pathologists from the Johns Hopkins
University in Baltimore has recently performed an ex-
tensive autopsy study with PAC patients and found a
local and distant disease progression in 30% and 70% re-
spectively [32]. Beside the fact, that the group was able
to correlate the DPC4-genetic status with a more meta-
static subtype, they also quantified metastatic patterns in
their report. In summary, the most frequent sites of
metastatic lesions were the liver and the peritoneum in
80% and 48% of cases respectively.
In a large clinical subset of PAC patients with locally
advanced, but initially not metastasized disease, that under-
went neoadjuvant chemoradiation with gemcitabine in
case of unresectable disease, our analysis showed newly
diagnosed metastases during follow-up predominantly
located in the liver (52%) and in the peritoneum (36%)
[2]. This seems to be in accordance with the previously
mentioned results from the autopsy study but with the
limitation of a clinical point of view, and thus not de-
tecting the subclinical disease and, therefore, having a
diagnostic bias. However, main sites of metastatic dis-
ease are the peritoneum and the liver. Whereas the liver
offers a putative target for RT, peritoneal disease dis-
semination requires systemic or even intra-peritoneal
cytostatic therapy, for example, in clinical trials.
Conclusion
However, according to our results we suggest to subdivide
PAC patients in a metastasized stage of disease into a first
group of patients with disseminated disease requiring
more or less immediate palliative RT because of clinic-
ally relevant symptoms. The second group consists ofmetastasized PAC patients in an oligometastasized stage
(one to four metastatic lesions) that may benefit from
local ablative therapies such as fractionated RT or even
RS, as did the patients undergoing RS and presenting an
OS of more than twelve months. For the first group, one
has to consider a rather short RT schedule in consider-
ation of the bad prognosis and short OS to avoid unneces-
sary long RT protocols to the cost of the remaining
lifetime. For the latter group, a RS procedure is an effect-
ive local ablative therapy and even in case of a rapidly pro-
gressive disease after treatment alio loco, the remaining
lifetime will not be affected as much as by fractionated RT
protocols, as previously mentioned.
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